pharmaceutical – name X

pharmaceutical – name X

https://namex.co
news business lifestyle
Tue, 16 Jun 2020 12:01:17 +0000
en-US

hourly

1

Home

https://secureservercdn.net/166.62.115.136/qm1.1bd.myftpupload.com/wp-content/uploads/2020/04/X-Logo-150×150.png
pharmaceutical – name X
https://namex.co
32
32

<a target="_blank" title="France gives its drugs industry a shot in the arm to tackle pandemic" href="https://ihghgel.com/france-gives-its-drugs-industry-a-shot-in-the-arm-to-tackle-pandemic/">France gives its drugs industry a shot in the arm to tackle pandemic</a>

France gives its drugs industry a shot in the arm to tackle pandemic

Tue, 16 Jun 2020 12:01:17 +0000

France gives its drugs industry a shot in the arm to tackle pandemic

<![CDATA[

MARCY-L’ETOILE, France (Reuters) – France’s president and top drugmaker announced plans on Tuesday to bolster domestic production of medicines as countries scramble to strengthen their healthcare industries to counter the coronavirus pandemic.

French President Emmanuel Macron delivers a speech after a visit at the French drugmaker’s vaccine unit Sanofi Pasteur plant in Marcy-l’Etoile, near Lyon, France, June 16, 2020. REUTERS/Gonzalo Fuentes/Pool

Drugmaker Sanofi, which is working on two potential coronavirus vaccines, said it would invest 610 million euros ($679 million) at two French sites to turn them into a hub dedicated to research, development and production of vaccines.

Speaking at Sanofi’s Marcy-L’Etoile facility, President Emmanuel Macron also pledged 200 million euros to help domestic research and manufacturing of medicines and said his government would announce plans on Thursday to bring back certain pharmaceutical production facilities to France.

“Everybody saw that during this crisis some commonly used drugs were no longer produced in France and Europe. So we must no longer just ask questions, but draw the conclusions,” Macron said at the Sanofi site near Lyon, central France.

There are currently no approved treatments or vaccines for COVID-19, the illness caused by the new coronavirus which has killed more than 431,000 globally. Drugmakers across the world are rushing to address that, while governments in turn are jostling to try to ensure they will be in line for supplies.

The issue has become particularly sensitive in France after Sanofi CEO Paul Hudson signalled in May that Europe was being too slow in supporting work on a vaccine and hinted U.S. patients might get any vaccine it develops first, given Washington had provided more funding.

Although Sanofi quickly back-pedalled, promising a vaccine would be made available worldwide simultaneously, the comments raised alarm over Europe’s lack of coordination.

In the latest sign European countries are now trying to catch up, a group formed by France, Germany, Italy and the Netherlands struck a deal on Saturday to secure 400 million doses of AstraZeneca’s potential vaccine.

The European Commission, meanwhile, received a mandate from EU governments on Friday to negotiate advance purchases of up to six vaccines using proceeds of an emergency fund of 2.4 billion euros ($2.7 billion).

($1 = 0.8837 euros)

Reporting by Gonzalo Fuentes, Michel Rose and Sudi Kar-Gupta, Writing by Matthias Blamont; Editing by Mark Potter and

]]>

UPDATE 1 -<a target="_blank" title="France gives its drugs industry a shot in the arm to tackle pandemic" href="https://ihghgel.com/france-gives-its-drugs-industry-a-shot-in-the-arm-to-tackle-pandemic/">France gives its drugs industry a shot in the arm to tackle pandemic</a>

UPDATE 1 -France gives its drugs industry a shot in the arm to tackle pandemic

Tue, 16 Jun 2020 12:00:52 +0000

UPDATE 1 -France gives its drugs industry a shot in the arm to tackle pandemic

<![CDATA[

MARCY-L’ETOILE, France (Reuters) – France’s president and top drugmaker announced plans on Tuesday to bolster domestic production of medicines as countries scramble to strengthen their healthcare industries to counter the coronavirus pandemic.

French President Emmanuel Macron delivers a speech after a visit at the French drugmaker’s vaccine unit Sanofi Pasteur plant in Marcy-l’Etoile, near Lyon, France, June 16, 2020. REUTERS/Gonzalo Fuentes/Pool

Drugmaker Sanofi, which is working on two potential coronavirus vaccines, said it would invest 610 million euros ($679 million) at two French sites to turn them into a hub dedicated to research, development and production of vaccines.

Speaking at Sanofi’s Marcy-L’Etoile facility, President Emmanuel Macron also pledged 200 million euros to help domestic research and manufacturing of medicines and said his government would announce plans on Thursday to bring back certain pharmaceutical production facilities to France.

“Everybody saw that during this crisis some commonly used drugs were no longer produced in France and Europe. So we must no longer just ask questions, but draw the conclusions,” Macron said at the Sanofi site near Lyon, central France.

There are currently no approved treatments or vaccines for COVID-19, the illness caused by the new coronavirus which has killed more than 431,000 globally. Drugmakers across the world are rushing to address that, while governments in turn are jostling to try to ensure they will be in line for supplies.

The issue has become particularly sensitive in France after Sanofi CEO Paul Hudson signalled in May that Europe was being too slow in supporting work on a vaccine and hinted U.S. patients might get any vaccine it develops first, given Washington had provided more funding.

Although Sanofi quickly back-pedalled, promising a vaccine would be made available worldwide simultaneously, the comments raised alarm over Europe’s lack of coordination.

In the latest sign European countries are now trying to catch up, a group formed by France, Germany, Italy and the Netherlands struck a deal on Saturday to secure 400 million doses of AstraZeneca’s potential vaccine.

The European Commission, meanwhile, received a mandate from EU governments on Friday to negotiate advance purchases of up to six vaccines using proceeds of an emergency fund of 2.4 billion euros ($2.7 billion).

($1 = 0.8837 euros)

Reporting by Gonzalo Fuentes, Michel Rose and Sudi Kar-Gupta, Writing by Matthias Blamont; Editing by Mark Potter and

]]>

<a target="_blank" title="Macron pledges 200 million euros to repatriate drug production to France" href="https://ihghgel.com/macron-pledges-200-million-euros-to-repatriate-drug-production-to-france/">Macron pledges 200 million euros to repatriate drug production to France</a>

Macron pledges 200 million euros to repatriate drug production to France

Tue, 16 Jun 2020 11:30:35 +0000

Macron pledges 200 million euros to repatriate drug production to France

<![CDATA[

French President Emmanuel Macron delivers a speech after a visit at the French drugmaker’s vaccine unit Sanofi Pasteur plant in Marcy-l’Etoile, near Lyon, France, June 16, 2020. REUTERS/Gonzalo Fuentes/Pool

PARIS (Reuters) – President Emmanuel Macron said the French government would launch a new initiative this week to repatriate production of some pharmaceutical products to France, pledging to make 200 million euros available to fund production capacity.

“Everybody saw that during this crisis some commonly used drugs were no longer produced in France and Europe. So we must no longer just ask questions but draw the conclusions,” Macron said at a Sanofi site near Lyon, central France.

Macron cited paracetamol as a drug that would be produced again in France.

Reporting by Michel Rose; Editing by Jon Boyle

]]>

IPO market braces for another busy week and Royalty<a target="_blank" title=" Pharma" href=" https://thisisonsale.com/"> Pharma</a> becomes the biggest deal year-to-date

IPO market braces for another busy week and Royalty Pharma becomes the biggest deal year-to-date

Tue, 16 Jun 2020 11:30:35 +0000

IPO market braces for another busy week and Royalty Pharma becomes the biggest deal year-to-date

<![CDATA[

The newly revived U.S. market for initial public offerings is expecting five deals to price this week, including the biggest deal of the year to date.

Royalty Pharma
RPRX,
+4079.10%
,
a buyer of biopharmaceutical royalties, priced its IPO late Monday at the high end of its range and upsized the deal, suggesting strong demand from investors. The company sold 77 million shares priced at $28 each to raise $2.2 billion. It originally planned to offer 70 million shares. That puts it ahead of the previous biggest deal, the IPO of Warner Music Group Corp., which raised $1.925 billion for the parent of Atlantic Records, Warner Records and Elektra Records.

“Royalty Pharma is highly profitable and generates strong cash flow, and it intends to pay a dividend with 2.3% yield at the midpoint,” said Renaissance Capital, a provider of institutional research and IPO ETFs, in commentary.

The shares will start trading later Tuesday on Nasdaq under the ticker symbol “RPRX.” There were 13 banks underwriting the deal, led by J.P. Morgan.

“Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies,” the company says in its IPO documents.

Royalty Pharma has built a portfolio of royalties by co-funding late-stage clinical trials in return for future royalties, and by acquiring existing royalties from the original developers of drugs. The portfolio includes such drugs as Tysabri, an immunosuppressive drug that is used to treat multiple sclerosis and Crohn’s disease, and Imbruvica, a small molecule drug used to treat B cell cancers such as mantle cell lymphoma.

“In 2019, a total of 22 therapies in our portfolio each generated 2019 end-market sales of more than $1 billion, including seven therapies that each generated 2019 end-market sales of more than $3 billion,” the company says.

Proceeds of the IPO will be used for general corporate purposes and to make acquisitions if appropriate.

The other deals this week are all in the biotech and health care sector.

Oncology biotech Forma Therapeutics Holdings Inc.
FMTX,

is planning to offer 11.8 million shares priced at $16 to $18 each to raise up to $212 million. The stock is expected to list on the Nasdaq under the ticker symbol “FMTX.”

Jefferies, SVB Leerink and Credit Suisse are the joint book-running managers. The company recorded a net loss of $34.8 million on collaboration revenue of $100.6 million in 2019, after net income of $5.3 million on collaboration revenue of $164.1 million in 2018.

Biotech Progenity Inc.
PROG,

is planning to offer 6.7 million shares priced at $14 to $16 each, raising up to $107.2 million. The company has applied to list on Nasdaq under the ticker symbol “PROG.”

Piper Sandler, Wells Fargo, Baird, Raymond James and BTIG are underwriters on the deal. Proceeds will be used for R&D and for working capital and general corporate purposes.

Don’t miss:Why virus stocks are driving market volatility

“We are a biotechnology company with an established record of success in developing and commercializing molecular testing products as well as innovating in the field of precision medicine,” says the prospectus.

Another oncology biotech Repare Therapeutics Inc.
RPTX,

plans to offer 7.4 million shares priced at $16 to $18 each to raise $133.2 million. The company has applied to list on Nasdaq under the ticker symbol ‘RPTX.”

Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler are underwriting the deal. Proceeds will be used to finance clinical trials, to fund other R&D and for working capital and general corporate purposes.

The company had a loss of $12.6 million in the first quarter, wider than the loss of $4.8 million posted in the year-earlier period.

Don’t miss:Mad dash for cash drives biggest month for follow-on offerings since the financial crisis

Rounding out the list is Chinese cancer diagnostics provider Genetron Holdings Ltd. That company is planning to offer 13 million American Depositary shares in the IPO, which is expected to price between $11.50 to $13.50 a share, to raise up to $175.5 million.

See also:Luckin Coffee shows how risky Chinese IPOs can be, but investors are just not listening

The stock is expected to be listed on the Nasdaq under the ticker symbol “GTH.” Credit Suisse and CICC are the joint book-running managers.

The company recorded a net loss of RMB676.0 million ($95.5 million) on revenue of RMB323.4 million in 2019, after a loss of RMB465.0 million on revenue of RMB225.2 million in 2018.

The Renaissance IPO ETF
IPO,
+4.09%

was up 3.9% Monday and has gained 25% in the year to date, easily outperforming the S&P 500
SPX,
+0.83%

which is down 6%.

The ETF has benefited from the inclusion in the fund of recent deals involving companies that recently went public and that are prospering in the pandemic, including Zoom Video Communications Inc.
ZM,
+8.88%

and Slack Inc.
WORK,
+0.03%

]]>

<a target="_blank" title="UPDATE 1-Royalty Pharma prices at top of range in second-biggest pharma IPO ever" href="https://ihghgel.com/update-1-royalty-pharma-prices-at-top-of-range-in-second-biggest-pharma-ipo-ever/">UPDATE 1-Royalty Pharma prices at top of range in second-biggest pharma IPO ever</a>

UPDATE 1-Royalty Pharma prices at top of range in second-biggest pharma IPO ever

Tue, 16 Jun 2020 04:30:54 +0000

UPDATE 1-Royalty Pharma prices at top of range in second-biggest pharma IPO ever

<![CDATA[

NEW YORK (Reuters) – Royalty Pharma RPRX.O on Monday sold $2.18 billion in stock after its U.S. initial public offering (IPO) was priced at the top end of the range, making it the second-largest pharmaceutical listing ever.

The deal is the latest in a string of successful U.S. IPOs in recent weeks and also signals that investor appetite for new stock is undiminished by recent market swings.

Royalty Pharma eclipses record label Warner Music Group’s WMG.O $1.93 billion IPO earlier this month as the largest U.S. listing so far this year, and is behind only Zoetis Inc (ZTS.N) as the largest pharma IPO of all time, according to data provider Dealogic.

It sold shares at $28 apiece, having last week set a target price range for the IPO of between $25 and $28 per share.

The company had aimed to sell 70 million shares but increased that amount by about 11% on the back of strong demand. The IPO values Royalty Pharma at $16.67 billion.

Royalty Pharma buys biopharmaceutical royalties and also helps fund new treatments. The company, which was founded in 1996, saw revenue rise 15% year on year for the first three months of 2020 to $500.9 million. Operating income fell 16% to $361.4 million in the same period.

Its investors include Adage Capital Management, General Atlantic and Nogra Group. The stock is due to start trading on Tuesday on the Nasdaq under the symbol RPRX. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs and Citigroup were among the lead underwriters on the IPO.

Reporting by Joshua Franklin and Rebecca Spalding in New York; additional reporting by Juby Babu in Bengaluru; Editing by Tom Hogue and Anil D’Silva

]]>

Trump battles <a target="_blank" title="health" href=" https://thisisonsale.com">health</a> officials over indoor rally
https://namex.co/trump-battles-health-officials-over-indoor-rally/

Mon, 15 Jun 2020 19:45:46 +0000

https://namex.co/trump-battles-health-officials-over-indoor-rally/

<!–<![CDATA[

**Want FOX News Halftime Report in your inbox every day? Sign up here.**

On the roster: Trump battles health officials over indoor rally – Biden’s veep shortlist isn’t getting shorter – GOP congressman ousted, opening door for Dems – Kilroy was here, and he brought paste 

TRUMP BATTLES HEALTH OFFICIALS OVER INDOOR RALLY
AP: “After months away from the campaign trail, President Donald Trump plans to rally his supporters next Saturday for the first time since most of the country was shuttered by the coronavirus. But health experts are questioning that decision. Trump will head to Tulsa, Oklahoma — a state that has seen relatively few COVID-19 cases. Yet the Tulsa City-County Health Department’s director told the Tulsa World over the weekend that he wished the Trump campaign would move the date back because of a ‘significant increase in our case trends.’ … Other health experts also cite the danger of infection spreading among the crowd and sparking outbreaks when people return to their homes. The Trump campaign itself acknowledges the risk in a waiver attendees must agree to absolving them of any responsibility should people get sick. … Scientists believe the virus spreads far more easily in crowded enclosed spaces than it does outdoors, where circulating air has a better chance of dispersing virus particles. … The CDC recommends cloth masks in places where people might shout or chant.”

Especially Tulsa’s Health Department director – Tulsa World: “In an interview with the Tulsa World on Saturday, Dr. Bruce Dart said Tulsa is seeing a ‘significant increase in our case trends’ that makes a large gathering like the rally dangerous for not only attendees, but the president himself. ‘I think it’s an honor for Tulsa to have a sitting president want to come and visit our community, but not during a pandemic,’ said Dart. … State officials on Saturday reported 225 new cases of COVID-19, once again marking a new high in daily increases for both the state and Tulsa County. … Dart said his concern stems from a sudden spike in cases he said likely comes from a combination of factors, but not increased testing.”

Supporters will get masks, sanitizer, temperature checks – USA Today: “Supporters who plan to attend President Donald Trump’s election rally in Oklahoma this week will be given temperature checks, hand sanitizer and face masks before entering the venue as safety measures to prevent the spread of the coronavirus, the Trump campaign said Monday. Trump campaign manager Brad Parscale announced the precautions in a tweet in what appeared to be the first steps the campaign has taken to address coronavirus concerns at the president’s first rally in more than three months. Last week, the campaign attempted to shield itself from any virus-related lawsuits from people who might get sick at the rally by including a liability disclaimer on the sign-up page for free tickets to the event.”

Expanded unemployment benefits will end in July – Politico: “National Economic Council Director Larry Kudlow reiterated Sunday the $600 additional weekly unemployment benefit created to aid those who lost their jobs due to the coronavirus pandemic will end in late July. ‘I mean, we’re paying people not to work. It’s better than their salaries would get,’ he said on CNN’s ‘State of the Union.’ ‘That might have worked for the first couple of months. It’ll end in late July,’ he added, saying the extra benefit was necessary during the height of the coronavirus lockdowns. Kudlow said that ‘almost all businesses’ understand the $600 additional benefit is ‘a disincentive.’ He said the Trump administration is instead ‘looking at a reform measure’ that will provide an incentive for returning to work, but it will not be as substantial. ‘It will not be as large, and it will create an incentive to work,’ he said.”

Republicans mark best-ever online fundraising day celebrating Trump – Fox News: “The Republican National Committee and the Trump campaign posted their largest online fundraising day ever on Sunday, bringing in $14 million across three entities on the president’s birthday — smashing their previous online fundraising record of $10 million on Oct. 19, 2016. The surge in cash comes as Republicans’ war chest continues to dwarf Democrats’ holdings, as it has for the entire primary cycle. Trump and the RNC – which have been building a fundraising juggernaut for more than three years – have roughly $255 million cash on hand, compared with the approximately $100 million the Joe Biden campaign and DNC have in their coffers. A competitive primary with numerous candidates on the Democratic side essentially stalled their effort to consolidate donations for months. The RNC, along with the Trump Make America Great Again Committee (TMAGAC) and Donald J. Trump for President, Inc. (DJTP), received an average online gift of $46, Fox News is told. Trump turned 74 on Sunday.”

Rothman: Trump distracts from Dems infighting – Commentary: “For several weeks, the Democratic Party has been at war with itself. An intraparty feud has broken out among the Democratic officials who govern America’s cities and their constituents who resent being aggressively overpoliced. Racial tensions in dark-blue urban enclaves have spilled into the streets. The public sector unions beholden to Democratic politicians in these municipalities are struggling to preserve their advantages against the forces of reform. The party is divided, almost down the middle, over the efficacy of radical measures that are anathema to the general public. All these conditions should theoretically benefit the incumbent president. So, what does Donald Trump do at this potentially advantageous moment? Randomly exhume the corpses of Confederate dead and put them on a pedestal. Of course.”

THE RULEBOOK: ONE FOR ALL
“As the safety of the whole is the interest of the whole, and cannot be provided for without government, either one or more or many, let us inquire whether one good government is not, relative to the object in question, more competent than any other given number whatever.” – John JayFederalist No. 4

TIME OUT: IT WAS FOR SCIENCE! 
Smithsonian: “In retrospect, perhaps toasting the success of a new medication he helped invent with several shots of vodka in Moscow was not a good idea. However, it was too late to go back. English research scientist Stewart Adams was faced with the consequences of his actions: a serious hangover. As he woke up that morning in 1971, Adams realized he needed to do something to relieve his throbbing headache, so he could coherently deliver an important speech at a pharmacological conference in a few hours. He reached for that new drug and swallowed a 600-milligram dose. Voila! … While the drug had been tested for pain in clinical trials, no one had yet tried it on an alcohol-induced headache. … Stewart Adams and his associate John Nicholson invented a pharmaceutical drug known as 2-(4-isobutylphenyl) propionic acid. It was later renamed ibuprofen and is now one of the world’s most popular nonsteroidal anti-inflammatory drugs (NSAIDs)…”

Flag on the play? – Email us at HALFTIMEREPORT@FOXNEWS.COM with your tips, comments or questions.

SCOREBOARD  
NATIONAL HEAD-TO-HEAD AVERAGE 
Trump: 41.8 percent 
Biden: 50.2 percent 
Size of lead: Biden by 8.4 points
Change from one week ago: First week of average
[Average includes: CNN: Trump 41% – Biden 55%; NBC News/WSJ: Trump 42% – Biden 49%; NPR/PBS/Marist: Trump 43% – Biden 50%; IBD: Trump 42% – Biden 49%; Monmouth University: Trump 41% – Biden 52%.]

BATTLEGROUND POWER RANKINGS
(270 electoral votes needed to win)
Toss-up: (103 electoral votes): Wisconsin (10), Ohio (18), Florida (29), Arizona (11), Pennsylvania (20), North Carolina (15)
Lean R/Likely R: (186 electoral votes) 
Lean D/Likely D: (249 electoral votes)
[Full rankings here.]

TRUMP JOB PERFORMANCE
Average approval: 40.6 percent
Average disapproval: 55 percent
Net Score: -14.4 points
Change from one week ago: ↓ 2 points
[Average includes: CNN: 40% approve – 57% disapprove; NPR/PBS: 42% approve – 55% disapprove; IBD: 42% approve – 52% disapprove; Gallup: 39% approve – 57% disapprove; CBS News: 40% approve – 54% disapprove.]

WANT MORE HALFTIME REPORT?
You can join Chris and Brianna every day on Fox Nation. It’ll be the same behind-the-scenes look at your favorite political note, only from their remote locations during this unprecedented time. Click here to sign up and watch!

BIDEN’S VEEP SHORTLIST ISN’T GETTING SHORTER
NYT: “Joseph R. Biden Jr.’s advisers have conducted several rounds of interviews with a select group of vice-presidential candidates and are beginning to gather private documents from some of them, as they attempt to winnow a field that features the most diverse set of vice-presidential contenders in history. The search committee has been in touch with roughly a dozen women, and some eight or nine are already being vetted more intensively. Among that group are two contenders who have recently grown in prominence, Representative Val Demings of Florida and Mayor Keisha Lance Bottoms of Atlanta. One well-known candidate, Senator Amy Klobuchar of Minnesota, has lost her perch as a front-runner. And some lower-profile candidates, like Senator Tammy Baldwin of Wisconsin, are advancing steadily in the search process. The New York Times spoke to an array of people who are familiar with the vice-presidential search and the activities of the Biden team, and the interviews yielded the fullest picture yet of the list of candidates Mr. Biden is considering, who is advancing and who may be fading, and the dynamics at play.”

Biden brings in massive haul in small dollar donations – Bloomberg: “Joe Biden’s campaign has transformed the virtual fundraisers made necessary by virus-related lockdowns into a money machine, drawing in tens of thousands of small-dollar donations from supporters eager to engage with celebrities or Biden allies. Biden pulled in $16 million from small donors in April, more than three times the $4.9 million President Donald Trump raised in small amounts for the month. Hosts that included breakout Democratic candidate Pete Buttigieg, celebrity yoga instructor Kyle Miller and 1970s ‘Wonder Woman’ star Lynda Carter. Campaigns report their May numbers to the Federal Election Commission on June 20. Unlike in-person fundraisers, which require travel, extensive planning and money to execute in strategically chosen locales, online events cost almost nothing to produce, allowing the campaign to innovate and take chances.”

Drucker: Well-heeled Republicans for Biden making their mark – WashEx: “Never Trump Republicans are coordinating efforts to oust President Trump, even consulting with Democratic groups in a bid to deploy resources efficiently and compare notes on effective messaging strategy. Republican Voters Against Trump, a new addition to the Never Trump ecosphere, is planning to spend $10 million on television and digital advertising in key battleground states. The group is focused on transforming Republican voters who backed Trump in 2016 into supporters of presumptive Democratic nominee Joe Biden. Top strategists at RVAT regularly touch base with Project Lincoln, a Never Trump group of prominent establishment Republicans already on the air with ads targeting the president. Both stay in touch with top Democratic outside groups, such as American Bridge, a liberal organization dedicated to opposition research, in a bid to maximize their campaign to take down Trump.”

GOP CONGRESSMAN OUSTED, OPENING DOOR FOR DEMS
The Roanoke Times: “Rep. Denver Riggleman, a first-term Republican from Nelson County, whose libertarian views and decision to officiate a same-sex marriage set in motion an intra-party challenge, lost his bid for renomination on Saturday. Bob Good, a former Campbell County supervisor and Liberty University employee, defeated Riggleman, whom President Donald Trump had endorsed, with 58% of the vote. Good has described himself as a ‘bright red Biblical and constitutional conservative.’ Good said he looks forward to making the district ‘bright red again.’ … Following his win, Good needs to resolve a problem with his failure to file his candidate qualification paperwork to the Virginia Department of Elections before the June 9 deadline. He filed it on Friday. …Good’s team has been reassuring people they are confident the Board of Elections will grant him an extension. The Republican Party of Virginia has requested the deadline be extended, arguing the deadline is usually the day the state-run primary is held.”

Ocasio-Cortez rakes in big bucks for primary – Fox News: “Rep. Alexandria Ocasio-Cortez, D-N.Y., once again proved her fundraising prowess by raising $2.4 million in just two months as she kicks up her campaign operation before her June 23 primary election, according to federal campaign finance reports she filed this week. Her April and May cash haul brings the total raised for her reelection bid to more than $10.5 million, making the freshman rep among the best fundraisers for the Democrats, along with House Intelligence Committee Chairman Adam Schiff, D-Calif., and House Speaker Nancy Pelosi, D-Calif., federal elections records show. Ocasio-Cortez, 30, is facing a spirited Democratic primary challenge from former TV journalist and CNBC anchor Michelle Caruso-Cabrera, who is running as a pro-business moderate in the Queens and Bronx district. She’s hit Ocasio-Cortez for opposing Amazon bringing one of its headquarters to New York. Caruso-Cabrera raised $930,000 during the same two-month period, bringing her total to more than $2 million for the entire election cycle.”

Dem establishment rallies to save Engel from Ocasio-Cortez-backed challenger – Politico: “House Majority Whip Jim Clyburn and Rep. Adam Schiff are endorsing Rep. Eliot Engel, the pair of Democratic heavyweights offering their full support as the embattled New Yorker fights to hold onto the seat he’s represented for more than three decades. Clyburn, the No. 3 House Democrat, and Schiff, chairman of the House Intelligence Committee, have considerable influence within Democratic politics. Both men praised Engel for his longtime service to his Bronx district and tenure as chairman of the House Foreign Affairs Committee in statements exclusively obtained by POLITICO on Sunday.”

Markey gets radical as he seeks to fend off Kennedy –  Politico: “The Massachusetts Democratic Senate primary faded into the background here in recent months as the coronavirus pandemic overshadowed everything else. But if the most recent Senate debate between Sen. Ed Markey and Rep. Joe Kennedy III is any indication, that’s about to change. The incumbent senator derided Kennedy on Monday as a ‘progressive in name only’ and called him out for working for a conservative Republican district attorney early in his career. Markey also slammed the four-term congressman for failing to lead on any number of issues, ranging from ‘Medicare for All’ to climate change to the militarization of law enforcement. Markey didn’t have much choice but to let it rip. He’s trailed Kennedy in most public polls taken this year, has less money in the bank and the Covid-19 crisis has served to complicate his task of capturing attention against the scion of the state’s most prominent political family.”

Republicans shift focus to China – NYT: “When Senator Martha McSally, one of the most politically endangered Republicans, was asked last month about reports that President Trump had brushed away warnings from his own aides about the looming threat of the coronavirus, she promptly pivoted. ‘I learned the day I entered the military, never trust a communist,’ Ms. McSally answered. ‘China is to blame for this pandemic and the death of thousands of Americans.’ … Fighting for their political lives amid twin domestic crises — a pandemic that has battered the economy — vulnerable Republican senators running for re-election are working to divert voters’ gazes half a world away and make their races a referendum on China. The tactic, party strategists say, is a way for Republicans to avoid defending the president’s handling of the virus, which has been met with widespread public disapproval, and instead offer up an alternative issue that already inspires fear and skepticism among voters.”

PLAY-BY-PLAY
SupCo rules gay workers protected from job discrimination, in big win for LGBT rights – Fox News

Pergram: What will November be about? – Fox News

Cuomo threatens to shut down again as social-distancing rules get broken  Fox News

AUDIBLE: MEAN SENATORS  
“Hey, Ron, somebody asked me about your investigations, and I wasn’t that nice.” – Sen. Brian Schatz, D-Hawaii, running into Sen. Ron Johnson, R-Wis., after speaking with Politico about the probes of prominent Dems and former Obama administration officials.

FROM THE BLEACHERS
“You outkicked your coverage in your response to Rick Randell on the cause of the Civil War. As you must know, the six Deep South states that originally seceded cited protection of their slavery-based agricultural society, but the remaining Confederate states, led by Virginia, didn’t secede until after Lincoln announced his intent to use military force to compel their return to the Union, a clear violation of a state’s right as commonly understood at the time. (A few decades earlier Abolitionists in Massachusetts had debated their own secession.) You came closer to the mark on your second try, that secession caused the war – not slavery or state’s rights. The South did not declare war – Lincoln’s provocations in South Carolina and Florida notwithstanding. Lincoln simply refused to allow secession. Under what provision of the Constitution did he do so? The real question is why did Lincoln choose war? Why didn’t he even call Congress back into session to debate the issue? Why did he refuse to meet with the South’s peace delegation in DC to discuss an amicable path forward? Why did he unilaterally author military incursions into South Carolina and Florida, in violation of the truce that followed secession and with the clear intent to provoke the South into firing the first shot? It’s often said, with misplaced pride, that the US endured a Civil War and half a million deaths to end slavery. The reality is that slavery, having outlived its economic reason for being, ended peacefully in the entire Western world with the cruel exception of the US. Because Lincoln chose war.” – Chris Sales, Fort Collins, Colo.

[Ed. note: I know you and those who hold dear this view of Lincoln as the villain of the story are sincere and earnest. And I know from years of hard-earned experience that no argument I am going to make – constitutional, political or moral – is likely to dissuade you, Mr. Sales. And I don’t agree with those who might say it makes you a bigot or a disloyal American to argue that we would have been better off if 150 years ago we proceeded as two nations instead of one and saw the continuation of state-sanctioned human chattel slavery for another two or three decades before it petered out into some variant of the apartheid-style system imposed after Reconstruction. There’s certainly enough wrong with how things worked out to imagine something differe–>

      _________________________________

#1 SALE AT: THISISONSALE.COM: SOMADERM & KETOGEN DIRECTLY FROM NEW U LIFE

GREAT DEALS ON - THIS IS ON SALE https://thisisonsale.com